Who makes Aspirin and indobufen mimetic?

Aspirin and indobufen mimetic is developed by Beijing Anzhen Hospital.

What development phase is Aspirin and indobufen mimetic in?

Aspirin and indobufen mimetic is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Aspirin and indobufen mimetic

Beijing Anzhen Hospital · FDA-approved active Small molecule Quality 3/100

At a glance

Generic name	Aspirin and indobufen mimetic
Sponsor	Beijing Anzhen Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE (PHASE4)
GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aspirin and indobufen mimetic CI brief — competitive landscape report
Aspirin and indobufen mimetic updates RSS · CI watch RSS
Beijing Anzhen Hospital portfolio CI